About teclistama b
Bispecific BCMA-CD3 antibody
Used for
- Treats adults with relapsed or refractory multiple myeloma after multiple previous treatments.
Usual adult dose
Given by specialist teams under the skin using step-up doses, then usually weekly or every two weeks; dose depends on body weight.
Common side effects
- Cytokine release syndrome, including fever and low blood pressure
- Infections and low blood-cell counts
- Nervous system problems, including confusion or headache
- Nausea, diarrhoea, tiredness, and injection-site reactions
Important warnings
- Can cause serious or life-threatening cytokine release syndrome and neurological toxicity.
- Treatment requires monitoring, especially after initial step-up doses.
- May cause serious infections and reduced blood-cell counts.
- Can harm an unborn baby; effective contraception is advised during treatment and for five months afterward.
Pregnancy
May cause fetal harm. Pregnancy status should be checked before treatment; use effective contraception during treatment and for five months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for five months after the last dose.
Interactions
- May affect how some medicines are processed; review medicines with the oncology team.
- Avoid live vaccines during treatment and until immune recovery.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.